Y-mabs enters clinic with new cancer candidate

In a first for the firm, Y-mabs has leveraged its new SADA platform to develop a drug heading into testing against multiple cancer targets.

Photo: Mikel Bilbao/AP/Ritzau Scanpix

Danish-American biotech firm Y-mabs has gotten the nod from the US Food and Drug Administration (FDA) for a phase I trial with cancer candidate GD2-SADA, according to a company press release.

The new candidate, targeting the treatment of malignant melanoma, sarcoma and small cell lung cancer, is the first to be developed using Y-mab’s SADA technology, which the firm licensed from Memorial Sloan Kettering Cancer Center (MSK) and Massachusetts Institute of Technology (MIT).

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs